Medical Companies

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTAÔ – formerly FIBRILLEXÔ) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration and European Medicines Agency. Tramiprosate (ALZHEMEDÔ), for the treatment of Alzheimer’s disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRILÔ), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. ( www.neurochem.com )

Neurochem Inc.
275 Armand-Frappier Blvd.
Laval, Québec H7V 4A7
Canada

Tel: (450) 680-4500
Fax: (450) 680-4501

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Caprion’s clinical-stage programs include Shigamabs®, a product for the treatment of Shigatoxin-producing E. coli bacterial infections, and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. CellCarta®, Caprion’s proprietary proteomics technology, provides Caprion with an effective means to identify novel drug targets, predict which therapeutics may be safer and more efficacious, and identify which patients may benefit most from a particular therapy. ( www.caprion.com )

Caprion Pharmaceuticals Inc.
7150 Alexander Fleming
Montréal, Québec H4S 2C8
Canada

Tel: (514) 940-3610
Fax: (514) 336-2343

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Cytochroma Inc. is an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of diseases and disorders related to vitamin D deficiency. The company has an advanced portfolio of new products targeting vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end stage renal disease. In addition, the company is developing novel vitamin D therapies to treat hyperproliferative disorders such as cancer and psoriasis. Cytochroma is a privately held company with offices in Markham, Ontario and Madison, Wisconsin. ( www.cytochroma.com )

Cytochroma Inc.
330 Cochrane Drive
Markham, Ontario L3R 8E4
Canada

Tel: (905) 479-5306
Fax: (905) 479-1287

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Neuromed is a privately held biopharmaceutical company developing the next generation of chronic pain drugs with pipeline programs in anxiety, epilepsy and cardiovascular disease such as hypertension. Located in Vancouver, Canada and Conshohocken, USA, the Company’s drug development programs are designed around validated clinical targets associated with large unmet markets. Neuromed exclusively focuses on calcium channels as drug targets and is the first company to take an orally available drug selectively targeting neuronal calcium channels into human clinical trials. Neuromed is a spin-off biotechnology company from the University of British Columbia founded by Dr. Terrance Snutch, who is also a professor in the Michael Smith Laboratories at UBC. ( www.neuromed.com )

Neuromed Technologies Inc.
301 – 2389 Health Sciences Mall
Vancouver, British Columbia V6T 1Z4
Canada

Tel: (604) 909-2530
Fax: (604) 909-2538

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
AlphaRx is developing several drug products in the therapeutic categories of Osteoarthritis and Infectious Disease. AlphaRx intends to file IND and NDA submissions with the FDA (when necessary) and license these products to other pharmaceutical companies for worldwide commercialization. The following is a list of AlphaRx’s Pharmaceutical Products in the pipeline: Name Indication Delivery Route Stage Indaflex Ô Osteoarthritis Topical Phase II Rifamsolin Ô Tuberculosis Oral Preclinical Zysolin Ô Pneumonia/Sepsis Parenteral Preclinical Ocusolin Ô Ocular Infection Topical Preclinical Binoxan Ô Ocular Inflammation Topical Preclinical ( www.alpharx.com )

AlphaRx Inc.
75 East Beaver Creek Unit 10
Richmond Hill, Ontario L4B 1B8
Canada

Tel: (905) 762-0745
Fax: (905) 762-0946

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
TOPIGEN is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN,s pipeline includes small molecule and RNA-based therapeutics. The Company,s Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit www.topigen.com. ( www.topigen.com )

Topigen Pharmaceuticals Inc.
2901 Rachel Suite 13
Montreal, Quebec H1W 4A4
Canada

Tel: (514) 868-0077
Fax: (514) 868-0011

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. RSD1235 (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for RSD1235 (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. An additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, and an open-label safety study evaluating recent-onset AF patients, called ACT 4, are ( www.cardiome.com )

Cardiome Pharma Corp.
6190 Agronomy Rd. 6Th Floor
Vancouver, British Columbia V6T 1Z3
Canada

Tel: (604) 677-6905
Fax: (604) 677-6915

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Inflazyme is a public company and we invite all current and prospective shareholders, partners, customers, and friends and other interested parties to browse our web site to learn more about the exciting science and opportunities at our Company. ( www.inflazyme.com )

Inflazyme Pharmaceuticals Ltd.
Suite 425 – 5600 Parkwood Way
Richmond, British Columbia V6V 2M2
Canada

Tel: (800) 315-3660
Fax: (604) 279-8711